Centrosomes play fundamental roles in mitotic spindle organization, chromosome segregation and maintenance of genetic stability. Recently, we have shown that centrosome aberrations occur early in chronic myeloid leukemia (CML) and are induced by imatinib in normal fibroblasts in vitro. To investigate the influence of BCR-ABL on centrosomes, we performed longterm in vitro experiments employing the conditionally p210BCR-ABL-expressing (tetracycline-inducible promoter) human monocytic cell line U937p210BCR-ABL/c6 as a model of CML chronic phase. Centrosome hypertrophy was detectable after 4 weeks of transgene expression onset, increasing up to a rate of 25.7% aberrant cells within 13 weeks of propagation. This concurred with clonal expansion of aneuploid cells displaying a hyperdiploid phenotype with 57 chromosomes. Partial reversibility of centrosome aberrations (26-8%) was achieved under prolonged propagation (14 weeks) after abortion of induction and bcr-abl silencing using small interfering RNA. Therapeutic doses of imatinib did not revert the aberrant phenotype, but counteracted the observed reverting effect of bcr-abl gene expression switch off. Suggesting a mechanistic model that features distinct abl-related tyrosine kinase activity levels as essential determinants of centrosomal integrity, this is the first report mechanistically linking p210BCR-ABL oncoprotein activity to centrosomal hypertrophy.
Introduction
The BCR-ABL tyrosine kinase is the key player in the pathogenesis of chronic myeloid leukemia (CML). The oncoprotein is capable of reprogramming the prior lineage commitment of hematopoietic stem and early progenitor cells, and induces illegitimate enlargement of clonal hematopoiesis and genetic instability that drives disease progression from chronic phase (CP) toward the fully transformed phenotype of blast crisis (BC). [1] [2] [3] The mechanisms responsible for the transition of CML CP into BC remain poorly understood, although it is generally accepted that an unrestrained BCR-ABL activity and accumulation of additional genetic alterations in hematopoietic stem/ progenitor cells are the primary determinants for expansion of increasingly malignant cell clones. [4] [5] [6] Molecular changes commonly observed in evolution to BC are oncogene mutations as well as additional nonrandom chromosomal abnormalities involving whole chromosomes. 3, 7, 8 Such massive genomic changes, collectively known as aneuploidy, are characteristic features of human tumors and contribute to the multistep model of tumorigenesis. [9] [10] [11] Several studies have provided evidence that centrosome aberrations (centrosomal hypertrophy) are linked to aneuploidy and constitute the possible cause of karyotype aberrations. [12] [13] [14] In normal cells, centrosomes serve as microtubule-organizing centers and organize the mitotic spindle, which mediates the strictly bipolar mitotic separation of chromatids. 15, 16 Moreover, centrosomes serve as part of the network that integrates positive and negative pathways for DNA repair, cell cycle arrest and mitotic entry. 17, 18 Therefore, defective centrosomes are considered to contribute to cancer progression by influencing cell proliferation and chromosomal stability. 9, 11, 19, 20 Recently, we have shown that centrosomal hypertrophy is an early event in the transformation process of bcr-abl-positive CML and occurs before chromosomal instability at the earliest identifiable step in CML development. 21 Imatinib, the selective inhibitor of the BCR-ABL tyrosine kinase gives rise to the same phenotype in normal cells in vitro. 22 Since bcr-abl is the first detectable genetic alteration in CML, early centrosome aberrations could be a direct consequence of BCR-ABL expression. To address this question, we performed long-term in vitro studies on human U937 monocytic cells expressing p210BCR-ABL under the control of a tetracycline-inducible promoter (Tet-On). Here, we report on the influence of p210BCR-ABL expression and imatinib treatment on centrosome status and clonal evolution.
Materials and methods

Cell lines and cell culture conditions
The U937 monocytic cell line clone c6 (U937p210BCR-ABL/c6) expressing p210BCR-ABL under the control of a Tet-On system was propagated, as described in the presence of 447 U/ml hygromycin B and 0.5 mg/ml geneticin (Gibco, Invitrogen, Karlsruhe, Germany) for transgene and On regulator selection, respectively. 23 The control cell line K562 and untransfected U937 monocytic cells (both American Type Culture Collection (ATCC), Manassas, VA, USA) were cultured in the same medium omitting hygromycin B and geneticin. For induction of BCR-ABL protein expression, 1 mg/ml doxocycline (Gibco) was added to the culture medium. To exclude effects of doxocycline itself on centrosome and karyotype status, bcr-abl-negative U937 control cells were identically treated with doxocycline. Triplicate cultures were used in all experimental arms. All cells were grown at an initial concentration of 5 Â 10 5 cells/ml medium. Cell number was determined by counting in a Neubauer chamber and viability was monitored by Trypan blue exclusion. The medium was replaced by fresh culture medium every 48 h. Imatinib (Novartis, Basel, Switzerland) treatment was performed at a concentration of 10 mM, as described previously. 22 
Centrosome staining and karyotype analysis
Cell fixation and centrosome immunostaining were performed, as described previously. 21, 22 To confirm centrosome-specific staining, sample subsets have been co-stained with anti-gammatubulin (SC-17788, Santa Cruz, CA, USA). In addition, anticentrin staining (C7736, Sigma, Taufkirchen, Germany) was performed to prove the presence of supernumerary/fragmented centrioles. Colcemid treatment was performed, as described by Giehl et al. 21 At least 10 metaphases out of six cultures were analyzed by G-banding technique and interpreted according to the International System for Human Cytogenetic Nomenclature. 24 Karyotypes and genomic copy number of the bcr-abl transgene in U937p210BCR-ABL/c6 cells were determined by fluorescence in situ hybridization (FISH). 25 In addition, sample ploidy was investigated by fluorescence-activated cell sorting (FACS) analysis of propidium iodide-stained cells according to the manufacturer's protocol (FACSscan flow cytometer, Becton Dickinson, Pharmingen, Germany).
Quantitative real-time polymerase chain reaction and point mutation analysis
Total RNA was extracted using RNeasy kit (Qiagen, Hilden, Germany). Quantification of bcr-abl transcript levels by quantitative real-time polymerase chain reaction (QRT-PCR) (LightCycler technology, Roche Diagnostics, Mannheim, Germany) was performed, as described previously. 4 As internal reference for gene expression normalization, beta-glucuronidase (gus) has been used as reported by Wang et al. 26 Relative transcript levels calculated from triplicate measurements were expressed as ratio bcr-abl/gus.
Western blot analysis
For preparation of protein lysates, 5 Â 10 7 cells were washed in ice-cold phosphate-buffered saline (PBS) and lysed in buffer containing 1% Nonidet P-40 (NP-40), 20 mM Tris pH 8.0, 160 mM NaCl, 10% glycerol, 1 mM ethylene diamine tetraacetic acid, 1 mM phenylmethylsulfonylfluoride, 1 mM orthovanadate and 10 mg/ml aprotinin at 41C for 30 min. Then, 100 mg (K562) and 300 mg (U937p210BCR-ABL/c6) of cleared protein lysate were separated by 10% Tris-HCl sodium dodecyl sulfatepolyacrylamide gel electrophoresis. Separated proteins were transferred to Immobilon-P membrane (Millipore, Bedford, MA, USA). For immunodetection of p210BCR-ABL, c-ABL and CrkL membranes were blocked at room temperature for at least 1 h in 1 Â Tris-buffered saline (TBS) (100 mM Tris pH 8.0 and 300 mM NaCl) plus 5% nonfat dry milk followed by primary antibody incubation. Except the anti-actin antibody (Calbiochem/Merck, Darmstadt, Germany), which was incubated for 3 h at room temperature, primary antibodies (anti-ABL, BD Bioscience, Heidelberg, Germany; anti-CrkL, Santa Cruz, Heidelberg, Germany) were incubated overnight in TBS-T (1 Â TBS and 0.05% Tween-20) plus 0.5% dry milk. Consecutively, blots were incubated for 2 h at room temperature with horseradish peroxidase-conjugated secondary antibody (SuperSignal West Femto kit, Pierce Biotechnology, Rockford, IL, USA). Chemiluminescence of antibody-antigen complexes was visualized using a ChemiDoc imager (BIO-RAD, Munich, Germany).
CrkL protein quantification was performed using Quantity One 4.5 software (BIO-RAD) and is expressed as ratio p-CrkL/pCrkL þ CrkL. Digital image processing was performed with Photoshop 7.0 (Adobe Systems Inc., San Jose, CA, USA).
Small interfering RNA experiments
For repression of c-ABL/BCR-ABL tyrosine kinase expression, abl-directed Small interfering RNA (siRNA) (Hs_ABL1_8_HP_-validated siRNA, Qiagen) and the appropriate controls (mitogen-activated protein kinase (MAPK1) siRNA; Alexa Fluor 488 nonsilencing siRNA) were transfected using the RNAi Human/ Mouse Starter Kit and HiPerFect Reagent (Qiagen) according to a fast-forward protocol of the manufacturer.
Results
Characterization of U937p210BCR-ABL/c6 cells and experimental design
To analyze the conditional context between p210BCR-ABL activity and the centrosomal status, we performed long-term experiments using U937p210BCR-ABL/c6 cells with inducible p210BCR-ABL expression (Tet-On) as in vitro CML CP model. Initially, cells were thoroughly tested with respect to transgene inducibility, proliferation rate, cell viability, and centrosome and karyotype status. U937p210BCR-ABL/c6 displays a complex hyperdiploid to hypertetraploid karyotype ranging from 47 to 94 chromosomes (Supplementary Table 1 ). One single clonal copy of the bcr-abl transgene was detected by FISH analysis on the short arm of chromosome 11 (11p). The rate of cells with spontaneous centrosomal aberrations was 5.8% resembling values observed in normal human hematopoietic cells (3%) 21 and in normal human dermal fibroblast cultures (5%). 22 This rendered U937p210BCR-ABL/c6 cells useful for our purpose because pathogenetically relevant aberration rates in CML blastic phase reach values up to 59% in patients and 34% in K562 cells. 21 Doxocycline itself had no influence on centrosomal status of U937 control cells. Induction of bcr-abl transgene expression led to 32-fold increase in bcr-abl transcript levels, p210BCR-ABL protein was detectable by western blot/ immunostaining after 16 h of induction. Densitometric analysis of BCR-ABL protein levels normalized to beta-actin revealed a sevenfold higher expression of the oncoprotein in K562 than in induced U937p210BCR-ABL/c6 cells. Decreased viability was observed under doxocycline induction and imatinib (10 mM) treatment. Therefore, whenever the percentage of dead cells in a culture exceeded 25%, all triplicate cultures of the respective experimental arm were ficollized (in 2-4 week turns) to carry on long-term propagation with viable cells only.
As illustrated in Figure 1 , long-term experiments started with three parallel arms (arm 1, BCR-ABL Off; arm 2, BCR-ABL Off þ 10 mM imatinib; arm 3, BCR-ABL On) running for a total period of 27 weeks. Each arm combined three identical cultures (triplicates). At regular intervals (sampling points, SP0-SP7), cell aliquots were withdrawn, preferably from all arms and their corresponding triplicates at the same time point, and analyzed. After propagation for 13 weeks (SP4 ¼ split up), cells from all triplicate cultures of arm 3 (BCR-ABL On) were combined, mixed and consecutively redistributed to a total of four subarms (3, 3A, 3B and 3C), each again representing triplicates. These subarms served to find out the long-term effect of further p210BCR-ABL expression (arm 3), the reversibility of BCR-ABL influence (subarm 3A), the effect of imatinib on cells under prolonged doxocycline induction (subarm 3B) and the putative p210BCR-ABL and centrosomal hypertrophy M Giehl et al proxy effect of imatinib toward abl-directed siRNA (subarm 3C, Figure 1 ). Owing to variation in proliferation and viability of differently treated cells, parallel sampling and analyses were not always possible for all arms at the same time points.
BCR-ABL expression induces centrosomal aberrations in a time-dependent manner
Comparison of uninduced (arm 1, BCR-ABL Off) and doxocycline-induced (arm 3, BCR-ABL On) U937p210BCR-ABL/c6 cells revealed a distinct time-dependent influence of p210BCR-ABL expression on the centrosome status ( Figure 2 Table 2 for the corresponding data set). Centriole marker (anti-centrin) staining of cells with supernumerary centrosomes (anti-gamma-tubulin) revealed multiple centrin-containing foci indicating an increased number of centrioles (n44 per cell). Simultaneous occurrence of regular paired and extra single centrin-containing foci within the same cell suggests inappropriate separation and duplication of centrioles or fragmentation of centrosomes into individual centrioles as underlying mechanism. The observed ploidy status (FACS analysis) rendered it unlikely that accumulation of supernumerary centrosomes may be due to failure in cytokinesis (data not shown). Kinase expression coincided with increased phosphorylation of CrkL (p-CrkL) that serves as surrogate marker of BCR-ABL tyrosine kinase activity. 27 However, some background activity of CrkL phosphorylation was detected pointing to either promoter leakage in the U937p210BCR-ABL/c6 system or to the involvement of other tyrosine kinases. Aside from increase in centrosome aberration rate, the prolonged induction of p210BCR-ABL expression led to decreased transcript levels of bcr-abl (bcr-abl/gus ratio), albeit the relative protein amount and its activity given by the rate of CrkL phosphorylation increased. While uninduced cells (arm 1) retained their complex hyperdiploid to hypertetraploid karyotype throughout the entire longterm experiment, karyotype analysis of induced cells (arm 3) at SP4 (13 weeks after induction) and SP7 (27 weeks after induction) revealed a trend in clonal evolution of U937p210BCR-ABL/c6 cells toward a complex hyperdiploid phenotype with 57 chromosomes (see Supplementary Table 1) . The observed proliferative advantage of this aneuploid phenotype proofed independent from transgene copy number as no amplification of chromosome 11 or the corresponding region (11p) was found by FISH analysis (data not shown).
Partial reversibility of the aberrant centrosomal status
To find out the reversibility of centrosomal aberrations in U937p210BCR-ABL/c6 cells, arm 3 was split at SP4 resulting in arm 3 and subarm 3A (Figure 1 ). While arm 3 resembles mere continuation of the preceding arm 3 (BCR-ABL On), cells in subarm 3A after being washed in PBS were further propagated for another 14 weeks omitting the inductor doxocycline.
Comparison of induced (arm 3) and turned off U937p210BCR-ABL/c6 cells (arm 3A, SP5 and SP6) revealed decrease in bcr-abl transcription, p210BCR-ABL protein expression and tyrosine kinase activity (Figure 2 panel c vs panel b ). This concurs with the decrease in number of cells displaying centrosomal aberrations. After 9 weeks of doxocycline-free propagation (SP6), 972.6% of cells showed aberrant centrosomes. In contrast, the rate of centrosomal aberrations in arm 3 (BCR-ABL On) remained constant (SP5, 2671.7%). The aberrant phenotypes seem to be unstable as their number decreased after p210BCR-ABL turn off (Figure 2 panel d) . This may also explain the reduced viability of induced cells when compared to controls. Since under prolonged culture (SP7, 27 weeks), still elevated levels of aberrant centrosomes were detected (872.4%) it has to remain open, whether full reversibility could be achieved. BCR-ABL turn off also seems to abrogate the clonal evolution toward a distinct hyperdiploid phenotype found in arm 3. Cytogenetic analysis of cells derived from subarm 3A at SP7 revealed a complex hypodiploid to hypertriploid karyotype comparable to that of arm 3 SP4 (Supplementary Table 1 ). Similar centrosome data were obtained when U937p210BCR-ABL/c6 cells of arm 3 SP4 exhibiting a rate of 25.771.7% aberrant cells were sowed in duplicate 24-well plates and treated with abl-directed siRNA for a period of 23 days while under continuous doxocycline induction (subarm 3C). We observed a decrease of bcr-abl transcript levels by 86% and centrosomal aberrations by nearly half (25.7-13%) compared to controls (data not shown), confirming the causative association between BCR-ABL expression and occurrence of centrosomal hypertrophy.
Imatinib does not reverse centrosomal aberrations in induced cells
To assess the antagonistic influence of imatinib on persistence of aberrant U937p210BCR-ABL/c6 cells, subarm 3B was treated with 10 mM imatinib starting after SP4. Although c-ABL and p210BCR-ABL protein expression, and p210BCR-ABL tyrosine kinase activity were dramatically reduced (Figure 2 panel d) , no considerable change in the rate of centrosomal aberrations constantly ranging around 2073.5% was detected (SP7). This observation suggests that imatinib, despite effectively inhibiting BCR-ABL tyrosine kinase activity, is not an antagonist of centrosomal hypertrophy. Contrarily, the drug counteracts the Figure 1 Schematic timetable of U937p210BCR-ABL/c6 long-term experiments. Three parallel arms, each representing triplicate cultures of U937p210BCR-ABL/c6 cells (arms 1-3), were propagated for a total period of 27 weeks. Abbreviations: SP, sampling points (n ¼ 8, SP0-SP7); BCR-ABL On, cells induced with doxocycline; BCR-ABL Off, cultures without doxocycline induction; þ /À Ima, cell culture medium containing and omitting imatinib (10 mM), respectively. After 13 weeks of propagation (SP4), all cells from triplicate cultures of arm 3 were combined, mixed and redistributed to four subarms (3, 3A, 3B and 3C) that were cultured for another 14 weeks (SP5-SP7). Experimental arms depicted in gray represent doxocycline-induced cultures (arms 3 and 3B).
p210BCR-ABL and centrosomal hypertrophy M Giehl et al abrogation of centrosome aberrations observed after transgene turn off (subarm 3A) suggesting that imatinib itself can trigger centrosomal aberrations by BCR-ABL-independent mechanisms. This is in line with data from arm 2 (BCR-ABL Off), where uninduced U937p210BCR-ABL/c6 cells were propagated with therapeutic doses of imatinib (10 mM, Figure 3 , SP0-SP7) and a time-dependent increase in aberrant cells was observed. In contrast to data derived from experimental arm 3, no trends toward clonal selection of distinct karyotypic phenotypes were detected in arm 2. This points to separate mechanisms of centrosomal hypertrophy and clonal evolution, only the latter being clearly BCR-ABL dependent.
Discussion
Centrosomal hypertrophy is one of the first lesions detectable in untreated CML and has been demonstrated to precede secondary karyotype instability associated with advanced stages of disease. 21 Albeit disease progression concurs with increase in bcr-abl mRNA and protein levels, the effect of BCR-ABL activity on the centrosome is still elusive.
Unfortunately, there is a considerable lack in the number of cell lines and animal engraftment systems that are suitable to model the initial steps of the disease, for example, the low-level expression of BCR-ABL in CML CP and to molecularly study the step-by-step genetic alterations accompanying disease progression. 28, 29 In fact, most commonly used CML-derived cell lines represent immortal cells from BC. Moreover, due to selection in culture, fast proliferating subclones with excessive expression of BCR-ABL have emerged over time. For example, K562 displays a hypertriploid karyotype with 11 copies of the bcr-abl, 30 a centrosomal aberration rate of 34% and a strong expression of the p210BCR-ABL tyrosine kinase when compared to primary Ph þ cells from CML CP patients (data not shown). To overcome such principal limitations, some authors set out for their studies to select subclones with graded expression of BCR-ABL within the range found in cells from CP to BC. 29 To model the initial phases of CML in vitro, we have employed U937p210BCR-ABL/c6 cells featuring a single-copy bcr-abl transgene with inducible p210BCR-ABL expression (TetOn) and, in the induced state, about sevenfold lower tyrosine kinase protein levels than those found in K562 cells. This enabled investigation of the centrosome status not simply in the presence or absence of p210BCR-ABL but also under continuous moderate expression of the oncoprotein.
Expression of the bcr-abl transgene over a period of 27 weeks led to a slow but steady increase in centrosomal aberration rates finally resembling values (26%) also observed in CML patients at the time of diagnosis. 21 Alike, the in vivo situation is reflected by the observed data on relative frequencies of numerical vs structural aberrations, as the accumulation of structural aberra- This is in line with reports on clonal evolution with nonrandom secondary cytogenetic aberrations in the majority of patients with progressing CML. 8, 31 Proliferative advantage of the emerged aberrant phenotype seems to strongly depend on the BCR-ABL oncoprotein as the number of aberrant cells continuously decreases after p210BCR-ABL turn off. This may explain the need for culture ficollization and the delayed doubling time of induced cells when compared to uninduced control cells observed by us and Hakansson et al. 23 Similarly, a reduction in the number of aberrant cells was achieved when p210BCR-ABL oncoprotein expression was inhibited using abldirected siRNA. Thus, our results suggest that the constitutive BCR-ABL tyrosine kinase activity is sufficient for either inducing centrosomal aberrations or granting proliferative advantage of a distinct aneuploid phenotype with aberrant centrosomes in U937 cells in vitro.
We further found that imatinib does not take effect as an antagonist with respect to the onset of centrosomal aberrations or clonal expansion of hitherto aberrant U937p210BCR-ABL/c6 cells. Instead, imatinib administration counteracted the normalizing effect of p210BCR-ABL expression turn off. These results confirm our previous work demonstrating that imatinib can induce centrosome and chromosome aberrations in bcr-ablnegative mammalian fibroblasts in a dose-dependent and species-independent manner. 22 Furthermore, the in vitro observations support the hypothesis that tyrosine kinase inhibitors may contribute to the emergence of clonal chromosomal abnormalities in BCR-ABL-negative progenitor cells of patients under long-term imatinib therapy as controversially discussed by several authors. 31, 32 The finding that both the constitutive tyrosine kinase activity of p210BCR-ABL and the complete abrogation of tyrosine kinase activities by imatinib treatment can lead to centrosomal aberrations suggests a functional connection between kinase activity and centrosomal duplication. One could imagine a tentative phosphoprotein that depends on a distinct level of phosphorylation for its proper function within the cellular network that controls signals for concerted centrosome duplication and mitosis. Any disturbance in the activity of the corresponding competent kinases (c-ABL, BCR-ABL) may change phosphorylation status and activity of the postulated protein and may result in an altered centrosomal fidelity. This hypothesis is in line with recent data provided by Barnes et al. 28, 29 who found that the amount, rather than the mere presence or absence of the BCR-ABL oncoprotein, is an important determinant of the degree of imatinib sensitivity and a key factor in clonal evolution of tumor cells. Therefore, the intracellular 'fine tuning' of abl-related tyrosine kinase activities may be an essential parameter in genomic instability, clonal evolution and disease progression. If this holds true, current tyrosine kinase inhibitor therapies resemble overkill, while completely abrogating BCR-ABL and c-ABL tyrosine kinase activities. Possibly, adjusted drug doses reducing tyrosine kinase activity to levels found in normal hematopoietic stem and progenitor cells could be advantageous for imatinib therapy.
The best candidate for such a phosphoprotein is the breast cancer 1 (BRCA1) E3 ubiquitin ligase that controls centrosome dynamics. 33 BRCA1 ubiquitination activity regulates the content of gamma-tubulin within the pericentriolar matrix, a centrosomal protein controlling microtubule nucleation and centrosome number. Activity loss or downregulation of BRCA1 results in an inappropriate accumulation of gamma-tubulin making centrosomes hyperactive and more likely to re-duplicate. 34 In human breast cell lines, inhibition of BRCA1 causes the centrosome duplication cycle to be disconnected from the cell cycle resulting in inappropriate centriole separation and centrosome re-duplication before mitosis. 35 These mechanisms may play a role in the pathogenesis of CML as there is experimental evidence that BRCA1 and c-ABL proteins interact and the latter phosphorylates the C terminus of BRCA1 in vitro contributing to the regulation of BRCA1 activity. 36 Moreover, downregulation of BRCA1 has been reported in BCR-ABL-expressing hematopoietic cells, further suggesting a mechanistic link among the BCR-ABL oncoprotein, BRCA1 and centrosomal hypertrophy. 37 The inclusion of BRCA1 into our hypothetic model is sufficient to explain how both constitutive p210BCR-ABL activity and inhibition of c-ABL by tyrosine kinase inhibitors may result in centrosomal hypertrophy.
Conclusion
We have shown for the first time that the activity of the p210BCR-ABL oncoprotein is functionally linked to centrosomal hypertrophy and concurs with clonal evolution of a distinct hyperdiploid phenotype in human monocytic U937 cells in vitro. Alike, the tyrosine kinase inhibitor imatinib can substitute the effect of BCR-ABL activity and triggers the emergence and maintenance of centrosomal abnormalities in p210BCR-ABLnegative cells, but not clonal evolution in vitro. We suggest a Figure  3 Imatinib and centrosome status. Uninduced U937p210BCR-ABL/c6 cells (BCR-ABL Off, arm 2) were propagated for a total period of 27 weeks in a medium containing 10 mM imatinib. At distinct sampling points (SP0-SP7), cell aliquots were withdrawn and monitored for centrosome status, relative bcr-abl transcript levels, c-ABL/p210BCR-ABL protein expression and p210BCR-ABL tyrosine kinase activity (CrkL phosphorylation). For abbreviations, see legend to Figure 2 . (see Supplementary Table 3 for the full data set).
p210BCR-ABL and centrosomal hypertrophy M Giehl et al mechanistic model that supports the hypothesis that the levels of c-ABL and BCR-ABL activities, not simply their presence or absence, may be essential determinants for maintenance of centrosomal and genomic stability. We hypothesize that proper quantification and therapeutic fine tuning of BCR-ABL and sc-ABL activities in tumor cells could contribute to improvement of current tyrosine kinase inhibitor-based therapies in CML.
